News & Media

In women's health, innovation is not just a buzzword but a necessity. Coologics, a forward-thinking femtech company, is at the forefront of this innovation with their platform technology, Vlisse, a patented, drug-free treatment for vaginal infections, including yeast infections and bacterial vaginosis.  In women's health, vaginal issues are paramount, with 30% of gynecological visits due to vaginitis , mainly from yeast infections and bacterial vaginosis (BV). The annual US

Coologics | Drug-free vaginal infection treatment Participating Groups: Ohio State Early Investor Network , Illini Angels Coologics is developing a drug-free intravaginal cooling device called Vlisse to treat vaginal infections without antibiotics. The Cleveland-based clinical-stage medical device company recently secured $3M in Seed funding led by Prevail and Dream Ventures, with participation from Ohio State Early Investor Network and Illini Angels. Funds will be used to a

Coologics , a US-based clinical-stage medical device company, has successfully closed an oversubscribed seed funding round, raising over $3 million for its innovative vaginal infection treatment device, Vlisse. Read more.

A Cleveland-based clinical-stage medical device company announced it has closed an oversubscribed $3 million seed funding round, doubling the initial $1.5 million target. Read more.

COOLOGICS , a clinical-stage medical device company, has announced the commencement of new, larger multi-center, open-label clinical trials for its innovative product, Vlisse. These trials will begin this month with the objective of gathering sufficient data to secure FDA clearance for the device. Read more.

COOLOGICS is launching multi-center clinical trials for its intravaginal cooling device to provide drug-free treatment for vaginal yeast infections and potentially reduce the risk of preterm births. Read more.

COOLOGICS , a clinical-stage medical device company, has announced the commencement of new, larger multi-center, open-label clinical trials for its innovative product, Vlisse. These trials will begin this month with the objective of gathering sufficient data to secure FDA clearance for the device. The site initiation visits are already scheduled, during which participating centers will receive comprehensive protocol training to ensure immediate enrollment and adherence to stu

COOLOGICSSearch company, a Cleveland-based clinical-stage medical device company, announced this month the initiation of multi-center, open-label clinical trials for VlisseSearch drug, its innovative intravaginal cooling device designed to treat vulvovaginal candidiasis (VVC)Search disease, commonly known as yeast infectionsSearch disease. Read more.

Abstract Background Vulvovaginal candidiasis (VVC), caused primarily by Candida albicans , is treated with anti-fungal drugs, often with variable efficacy and relapses. New therapeutic strategies, including drug-free alternatives, are needed. Upon overgrowth or environmental triggers, C. albicans commensal yeast transitions into hyphae resulting in an aberrant immunopathologic neutrophil response that contributes to the characteristic signs and symptoms of vaginitis. The pur

To determine the effectiveness and speed of symptom relief of a vaginal cooling device (VCD) in the treatment of Vulvovaginal candidiasis (VVC). VVC causes itching, burning, pain or irritation, erythema, edema, excoriation and impacts quality of life, loss of confidence and self-esteem, and difficulties with sexual relations. Standard oral and local antifungal therapy have shortcomings including delayed symptomatic relief, increased drug resistance, decreased efficacy, side e